US 11,866,425 B2
Diacylglycerol acyl transferase 2 inhibitors
Markus Boehm, Mansfield, MA (US); Shawn Cabral, Groton, CT (US); Matthew S. Dowling, Old Lyme, CT (US); Kentaro Futatsugi, Qunicy, MA (US); Kim Huard, Berkeley, CA (US); Esther Cheng Yin Lee, Newton, MA (US); Allyn T. Londregan, Barrington, RI (US); Jana Polivkova, Mystic, CT (US); David A. Price, Concord, MA (US); and Qifang Li, Stonington, CT (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Jun. 11, 2021, as Appl. No. 17/345,064.
Application 17/345,064 is a continuation of application No. 16/793,441, filed on Feb. 18, 2020, granted, now 11,034,678.
Application 16/793,441 is a continuation of application No. 15/977,238, filed on May 11, 2018, abandoned.
Application 15/977,238 is a continuation of application No. 15/674,914, filed on Aug. 11, 2017, granted, now 10,071,992, issued on Sep. 11, 2018.
Claims priority of provisional application 62/377,137, filed on Aug. 19, 2016.
Prior Publication US 2021/0309646 A1, Oct. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/505 (2006.01); A61P 3/00 (2006.01); A61P 3/10 (2006.01); A61P 3/06 (2006.01); C07D 405/14 (2006.01); C07D 401/14 (2006.01); A61K 31/506 (2006.01); A61K 45/06 (2006.01); C07D 409/14 (2006.01)
CPC C07D 405/14 (2013.01) [A61K 31/506 (2013.01); A61K 45/06 (2013.01); C07D 401/14 (2013.01); C07D 409/14 (2013.01); A61P 3/00 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); C07B 2200/13 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A method for treating hyperlipidemia, dyslipidemia,
atherosclerosis, hypertriglyceridemia, or hyper apo B lipoproteinemia, in humans comprising the step of administering to a human in need of such treatment a therapeutically effective amount of a compound according to Formula (I) or a pharmaceutically acceptable salt of said compound;

OG Complex Work Unit Chemistry
wherein
D1 and D2 are each independently N or CH;
R1 is H, or (C1-C2)alkyl optionally substituted with one or two substituents each independently selected from fluoro and (C3-C6)cycloalkyl;
R2 is H or fluoro;
R3 is,

OG Complex Work Unit Chemistry
R4 is H, cyano, or (C1-C4)alkyl optionally substituted with one or two substituents each independently selected from —OH and —S(O)2R6;
R5 is H or —OH, and
R6 is (C1-C4)alkyl.